Ruxolitinib is an orally active, selective JAK1/2 inhibitor that modulates cytokine signaling, suppresses tumor proliferation, and induces toxic mitophagy, with therapeutic potential in myeloproliferative neoplasms and inflammatory conditions.
Usually ships within 24 hours.